Investment Thesis
Lyell Immunopharma is a clinical-stage biotech company with minimal revenue ($2K) and substantial operating losses (-$44.3M). While the company maintains a strong balance sheet with $90.8M in cash and no debt providing approximately 2+ years of runway, the rapid cash burn rate (-$38.5M operating cash flow) combined with pre-commercial stage operations creates significant execution risk without demonstrated clinical trial success or partnership milestones.
Strengths
- Strong balance sheet with $273.7M stockholders' equity and zero debt
- Solid cash position ($90.8M) providing operational runway
- Excellent current ratio of 7.23x indicates short-term liquidity strength
- No long-term debt obligations limiting financial distress risk near-term
Risks
- Minimal revenue generation ($2K) indicates pre-commercial stage with unproven commercialization
- Annual operating cash burn of $38.5M with limited runway relative to typical biotech development timelines
- Negative operating and net margins (-2.2M% and -1.2M% respectively) indicating far from profitability
- Clinical-stage risk: success dependent on trial outcomes, regulatory approval, and market adoption
- Capital requirements likely to increase as pipeline advances through development stages
Key Metrics to Watch
- Operating cash burn rate trend and projected runway duration
- Clinical trial progress and regulatory milestones for lead candidates
- Quarterly revenue growth and commercial partnerships or licensing deals
- Cash position and financing activities for future capital raises
Financial Metrics
Revenue
2.0K
Net Income
-24.2M
EPS (Diluted)
$-1.10
Free Cash Flow
-38.6M
Total Assets
350.6M
Cash
90.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,213,050.0%
Net Margin
-1,207,650.0%
ROE
-8.8%
ROA
-6.9%
FCF Margin
-1,929,950.0%
Balance Sheet & Liquidity
Current Ratio
7.23x
Quick Ratio
7.23x
Debt/Equity
0.00x
Debt/Assets
21.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:46:25.331548 |
Data as of: 2026-03-31 |
Powered by Claude AI